NeuroKaire
Precision Medicine for Psychiatry and Neurology
Company Overview
Snapshot
Founded in August 2018 by Talia Cohen Solal and Daphna Laifenfeld, NeuroKaire operates with 11–50 employees. The company has secured funding across eight rounds from seven investors, with GreyBird Ventures notably leading a round in June 2024. In May 2026, NeuroKaire received a grant from the BIRD Foundation.
Business overview
NeuroKaire, formerly Genetika+, specializes in developing personalized medical testing tools for psychiatric and neurological conditions. The company's core technology involves an AI-powered platform that predicts optimal drug treatments for patients, aiming to accelerate treatment efficacy, reduce side effects, and optimize dosing. NeuroKaire serves the healthcare and biopharma industries, focusing on digital medical diagnostics and decision support for clinicians, patients, and pharmaceutical companies in markets such as the United States and Europe.
Strategic signal
In September 2025, NeuroKaire launched what it describes as the world's first blood test to personalize depression treatment. This development signals a significant advancement in precision medicine for mental health, moving beyond traditional trial-and-error approaches. For investors, this indicates NeuroKaire's potential to capture a substantial market share in psychiatric diagnostics and therapeutics, validating its AI-powered approach and positioning the company for commercialization in key markets.
Log in to access full profile ›Company Intelligence Q&A
- What is NeuroKaire's primary focus?
- NeuroKaire specializes in precision medicine for psychiatry and neurology, developing personalized medical testing tools to optimize drug therapy for patients.
- When was NeuroKaire founded and by whom?
- NeuroKaire was founded in August 2018 by Talia Cohen Solal and Daphna Laifenfeld.
- What significant grant did NeuroKaire receive in 2026?
- In May 2026, NeuroKaire received a grant from the BIRD Foundation for new U.S.-Israel projects in mental health.
- What was a key product launch for NeuroKaire in 2025?
- In September 2025, NeuroKaire launched the world’s first blood test to personalize depression treatment.
- What was the company's prior name?
- NeuroKaire was formerly known as Genetika+.